登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>ROBO1 >RB1-H82E5

Biotinylated Human ROBO1 Protein, His,Avitag™ (MALS verified)

分子别名(Synonym)

ROBO1,DUTT1

表达区间及表达系统(Source)

Biotinylated Human ROBO1, His,Avitag (RB1-H82E5) is expressed from human 293 cells (HEK293). It contains AA GIn 26 - Pro 897 (Accession # Q9Y6N7-1).

Predicted N-terminus: GIn 26

Request for sequence

蛋白结构(Molecular Characterization)

ROBO1 Structure

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 99.2 kDa. The protein migrates as 100-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 0.2 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

ROBO1 SDS-PAGE

Biotinylated Human ROBO1, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

ROBO1 SEC-MALS

The purity of Biotinylated Human ROBO1, His,Avitag (Cat. No. RB1-H82E5) is more than 90% and the molecular weight of this protein is around 100-122 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

ROBO1 ELISA

Immobilized Anti-ROBO1 Antibody, Mouse IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human ROBO1, His,Avitag (Cat. No. RB1-H82E5) with a linear range of 2-31 ng/mL (QC tested).

Protocol

 

活性(Bioactivity)-FACS

ROBO1 FACS

2e5 of Anti-ROBO1 CAR-293 cells were stained with 100 μL of 3 μg/mL of Biotinylated Human ROBO1, His,Avitag (Cat. No. RB1-H82E5) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

Protocol

 
评论(0)
  1. 180XXXXXXX7
  2. 0人赞
  3. 购买了acro的biotinylated humanCTLA 4用Fortebio方法,测试了在不同PH下,伊匹木单抗结合CTLA4的亲和力,测试结果和Acro的SPR的数据是一致的。效果非常好。
  4. 2022-4-25
  1. 185XXXXXXX1
  2. 0人赞
  3. 之前实验用的其他家筛选,阳性率很低,后来就想着换到这家试试,比较发现ACRO蛋白能更有效拿到我需要的分子,后面买蛋白就首选ACRO!
  4. 2024-5-10
  1. 151XXXXXXX5
  2. 0人赞
  3. 本次购买的产品主要用来做噬菌体淘选实验的,实验价格很好,我们在进行第二轮筛选的时候就出现了富集,为我们后续实验节省了时间
  4. 2022-12-9
 
ACRO质量管理体系
 
 

背景(Background)

ROBO1 is a member of the ROBO immunoglobulin superfamily of proteins, and it plays a crucial role in cell motility and migration during embryogenesis and organogenesis. In addition, evidence showed that ROBO1 might drive migration and invasion in malignant cells, such as glioma and breast cancer, which might play a role in cancer aggressiveness. In contrast, some studies suggested that ROBO1 pathways play a key role in tumors by acting as a tumor suppressor, especially in cell invasion.

 

前沿进展

Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients
Nakatsura, Takenouchi, Kataoka et al
Int J Mol Sci (2025) 26 (5)
Abstract: Although CD19 CAR-T has been highly effective against B-cell blood cancers, there are few reports of successful treatments for solid cancers, probably because there are few protein antigens specifically expressed on the surface of the cancer cell membrane. The key to developing a groundbreaking CAR-T cell therapy effective against solid cancers is to "overcome the heterogeneity of cancer antigens". For this purpose, it is necessary to target multiple cancer antigens simultaneously. In this study, we performed immunohistochemical analysis of various solid cancer specimens using antibodies against ROBO1, EphB4, CLDN1, and LAT1 in addition to GPC3, which we have previously studied. These antigens were frequently expressed in various solid cancers but shown to be rarely expressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. Although ROBO1 and GPC3 are often expressed in cytoplasm, there are also cases in which they are expressed on the cell membrane depending on the type of cancer. On the other hand, it has been revealed that three antigens-EphB4, CLDN1, and LAT1-are frequently expressed only on the cell membrane of cancer cells in various solid cancers, suggesting that they may be ideal targets for CAR-T cell therapy.
MYC regulation of the miR-92-Robo1 axis in Slit-mediated commissural axon guidance
Majumder, Khot, Suriyaarachchi et al
Mol Biol Cell (2025) 36 (4), ar50
Abstract: In the developing spinal cord, translational repression of Robo1 expression by microRNA-92 (miR-92) in precrossing commissural axons (CAs) inhibits Slit/Robo1-mediated repulsion facilitating commissural axon projection and midline crossing; however, the regulatory mechanisms governing miR-92 expression in the developing commissural neurons are currently lacking. Here, we propose that the transcription factor MYC regulates miR-92 expression in the developing spinal cord (of either sex) to control Robo1 levels in precrossing CAs, modulating Slit/Robo1-mediated repulsion and midline crossing. MYC, miR-92, and Robo1 are differentially expressed in the developing chicken spinal cord. MYC binds to the promoter region upstream of the gga-miR-92 gene in vitro. MYC knockdown dramatically decreases miR-92 expression and increases chicken Robo1 (cRobo1) levels. In contrast, overexpression of MYC significantly induces miR-92 expression and reduces cRobo1 levels. MYC knockdown or overexpression results in significant inhibition or induction of miR-92 activity in the developing chicken spinal cord, respectively. Disruption of the MYC-dependent regulation of the miR-92-cRobo1 axis affects Slit2-mediated CA growth cone collapse in vitro and impairs CA projection and midline crossing in vivo. These results elucidate the role of the MYC-miR-92-cRobo1 axis in Slit2/Robo1-mediated CA repulsion and midline crossing.
Identification of 68 HLA-A24 and -A2-restricted cytotoxic T lymphocyte-inducing peptides derived from 10 common cancer-specific antigens frequently expressed in various solid cancers
Kinoshita, Takenouchi, Tsukamoto et al
Neoplasia (2025) 61, 101135
Abstract: Targeting cancer antigens expressed in cancer cells is necessary to develop cancer-specific immunotherapy. We have performed immunohistochemical analysis of various solid cancer specimens, adding ROBO1, AFP, TGFBI, EphB4, CLDN1, and LAT1 to the previously studied glypican-3 (GPC3), HSP105α, FOXM1, and SPARC, and found that these 10 common cancer antigens are sufficient to cover most solid cancers. These antigens were frequently expressed in various solid cancers but shown to be rarely ex-pressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. In this study, we predicted 72 and 73 peptides that bind to HLA-A24 and -A2 in silico from the full-length amino acid sequences of these 10 common cancer antigens and immunized each HLA transgenic mouse with a cocktail of synthesized peptides together with the poly I:CLC three times weekly to analyze the antigen-specific immune response. As a result, 68 peptide sequences (30 and 38, respectively) were identified that had higher cytotoxic T lymphocyte (CTL) induction ability than GPC3 298-306 and GPC3 144-152 used in the clinical trials. Furthermore, experiments with cocktail peptide vaccines using mouse models expressing subcutaneous tumors of each antigen showed promising results in terms of safety and efficacy. These peptides identified in this study, derived from 10 common cancer antigens covering all solid cancers, are expected to be clinically applicable as cocktail peptide vaccines.Copyright © 2025. Published by Elsevier Inc.
The microcephaly-associated transcriptional regulator AUTS2 cooperates with Polycomb complex PRC2 to produce upper-layer neurons in mice
Shimaoka, Hori, Miyashita et al
EMBO J (2025) 44 (5), 1354-1378
Abstract: AUTS2 syndrome is characterized by intellectual disability and microcephaly, and is often associated with autism spectrum disorder, but the underlying mechanisms, particularly concerning microcephaly, remain incompletely understood. Here, we analyze mice mutated for the transcriptional regulator AUTS2, which recapitulate microcephaly. Their brains exhibit reduced division of intermediate progenitor cells (IPCs), leading to fewer neurons and decreased thickness in the upper-layer cortex. Increased expression of the AUTS2 transcriptional target Robo1 in the mutant animals suppresses IPC division, and transcriptomic and chromatin profiling shows that AUTS2 primarily represses transcription of genes like Robo1 in IPCs. Regions around the transcriptional start sites of AUTS2 target genes are enriched for the repressive histone modification H3K27me3, which is reduced in Auts2 mutants. Furthermore, we find that AUTS2 interacts with Polycomb complex PRC2, with which it cooperates to promote IPC division. These findings shed light on the microcephaly phenotype observed in the AUTS2 syndrome.© 2025. The Author(s).
Showing 1-4 of 703 papers.
Powered by BizGenius
 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
ROBO1靶点信息
英文全称:Roundabout homolog 1
中文全称:轴突导向受体蛋白(ROBO)1
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:0详情
最高研发阶段:无进展
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定